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The polybrominated diphenyl ethers (PBDEs)
are a series of 209 possible brominated
diphenyl ethers (BDEs) that differ in the num-
ber and position of bromine atoms [Agency for
Toxic Substances and Disease Registry
(ATSDR) 2004]. Three kinds of PBDE blends
were manufactured and marketed as standard
mixtures: Penta-BDE (containing penta-,
tetra-, and some hexabrominated congeners),
Octa-BDE (containing from hexa- to deca-
brominated congeners), and Deca-BDE (97%
deca-BDE and 3% nonbrominated con-
geners). Standard mixtures of PBDEs have
been used extensively as ﬂame retardants over
the past 30 years in a variety of consumer
products (e.g., plastics, foams, electronics).
The PBDEs are very stable compounds and are
not chemically bonded to material they are
intended to protect from burning. Therefore,
it is not unexpected that PBDEs are being
found more and more in environmental media
[reviewed by Domingo (2004), Hites (2004),
and Law et al. (2006)], and possible exposure
to them has become a public health concern.
The endocrine-disrupting potential of
PBDEs has been studied, mostly in regard to
their effect on thyroid hormone homeostasis.
Commercial PBDE formulations reduce thy-
roid hormone levels and induce thyroid hyper-
plasia in rodents (Darnerud et al. 2007; Stoker
et al. 2004). Increased thyroid hormone clear-
ance by induction of metabolic enzymes, and
displacement of thyroxine from its transport
protein have been suggested as mechanisms of
thyroid disruption (reviewed by Siddiqi et al.
2003). Neurobehavioral alterations were
observed in rodents treated neonataly with
PBDEs (Viberg et al. 2002, 2003), but these
alterations have not been linked to hormonal
activity. Recent studies have linked PBDE to
estrogenic effects in vitro (Meerts et al. 2001)
and to adverse effects in sexual development
and behavior in rodents (Ceccatelli et al. 2006;
Kuriyama et al. 2005; Lilienthal et al. 2006;
Stoker et al. 2004).
In vivo estrogen bioassays are classically
based on responses of reproductive organ tis-
sues in rodents. Estrogens induce many physio-
logical changes in the mammalian female
reproductive tract and mammary glands.
Immature or ovariectomized (OVX) adult
rodents have served as the standard bioassay
model for estrogenic activity. In the adult
mouse, estrogen target organ size and histologic
characteristics regress to a nonstimulated state
after ovariectomy, thus providing a model free
of endogenous estrogens in which their physio-
logic effects can be studied. In OVX animals,
estrogens increase uterine wet weight (Evans
et al. 1941; Gordon et al. 1986) and uterine
epithelial height (UEH) and vaginal epithelial
thickness (VET) (Suzuki et al. 1996; Ulrich
et al. 2000) after a few days of treatment. In the
uterus, the columnar epithelial cells become
taller, with a concomitant increase in cyto-
plasmic volume; they also proliferate, causing
overcrowding and a pseudostratified appear-
ance. In the vagina, the single squamous epithe-
lial layer of the OVX mouse becomes a
multicell layer after estrogen treatment.
Breast cancer cells in culture also serve as
an estrogen bioassay. Although most normal
mammary epithelial cells have no estrogen
receptors (ERs) and depend on stromal inter-
actions in their response to estrogen, carcino-
mas often express ERs, and estrogens induce
their growth (Hahnel and Twaddle 1971;
Osborne et al. 1985; Welsch et al. 1981). The
fact that estrogens increase proliferation of
neoplastic mammary epithelium in vitro is the
basis of cell proliferation assays (Weichselbaum
et al. 1978).
In vivo uterotrophic assays and in vitro
breast cancer cell proliferation assays have
been used extensively to assess the estrogenic-
ity of environmental chemicals (Clode 2006;
Soto et al. 1995). In the present study, we
used an estrogen-responsive human cancer cell
line, MCF-7, and the OVX mouse as bioassay
models to assess the estrogenicity of DE-71, a
standard Penta-BDE mixture of PBDEs com-
monly used in consumer goods.
Materials and Methods
Test chemicals. We purchased dimethyl sulfox-
ide (DMSO), 1,3,5[10]estratriene-3,17-β-diol
[17β-estradiol, (E2)], and β-estradiol-3-ben-
zoate (EB) from Sigma-Aldrich (St. Louis,
MO). Corn oil was purchased from ICN
Biomedicals Inc. (Aurora, OH). Fulvestrant
[ICI 182 780 (ICI)] was a gift from Astra
Zeneca (Macclesfield, Cheshire, UK). The
PBDE congener mixture DE-71 (lot no.
9550OF05A) was a gift from the Great Lakes
Chemical Corporation (West Lafayette, IN);
the congener composition was reported previ-
ously (Qiu et al. 2007). There were no
detectable dioxins in the DE-71 lot used, but it
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Researchwas not tested for furan content (Hites R,
Qiu X, personal communication). DMSO was
used as the primary solvent for all treatment
chemicals, and the DMSO solutions were fur-
ther diluted in corn oil for animal treatments.
DE-71 remained in solution in DMSO at all
doses used, but vials were still vigorously vor-
texed for several seconds immediately before
treatment. DE-71 prepared for in vivo treat-
ments was maintained in suspension in corn
oil by continuous stirring while the needle was
ﬁlled, and animals were dosed immediately.
Cell proliferation measurements. To meas-
ure cell proliferation, we used the colorimetric
assay developed by Mosmann (1983) with
minor modiﬁcations. Cells were regularly main-
tained in growth medium [i.e. minimum essen-
tial media (MEM; Gibco/Invitrogen; Carlsbad,
CA) supplemented with L-glutamine (2 mM;
Gibco/Invitrogen), nonessential amino acids
(0.1 mM; Gibco/Invitrogen), HEPES buffer
(10 mM, Gibco/Invitrogen), and 5% vol/vol
bovine growth serum (Hyclone, Logan, UT)].
To minimize basal hormonal activity during
assays, cells were incubated in basal medium
(i.e., phenol red free MEM supplemented with
2 mM L-glutamine, 0.1 mM nonessential
amino acids, 10 mM HEPES, and 3% vol/vol
dextran-coated charcoal-stripped bovine
growth serum).
For the cell proliferation assay, cells cul-
tured with growth medium were plated in
24-well dishes (15,000 cells/well). The day after
plating, culture medium was changed to basal
medium. Starting 2 days after changing to basal
medium, cells were cultured in treatment
medium (basal medium plus treatment) for a
total of 10 days, changing the treatment
medium every 2 days. On day 10, cells were
incubated in tetrazolium MTT [3-(4,5-
dimethylthiazolyl-2)2,5-diphenyltetrazolium
bromide] for 2 hr, then lysed in acid iso-
propanol. Reduced (blue) MTT absorbance
was read at 570 nm.
To conﬁrm the MTT absorbance corre-
lated with cell growth and not increased meta-
bolic activity, in some experiments we
included additional plates treated in parallel
for DNA determination. After 10 days of
treatment, cells were washed twice with phos-
phate-buffered saline and incubated for 10 sec
in cold methanol. After removing the
methanol, we allowed cells to dry at room
temperature. Cells were then dissolved in
0.5 M sodium hydroxide by rocking in a
humidified 37°C chamber for 30 min.
Samples were then transferred to microtubes
and incubated at 65°C for 1 hr. Sample
(100 µL) was diluted in TNE buffer (10 mM
Tris, 0.1 M NaCl, 1 mM EDTA, pH 7.4)
containing 0.1 mg/mL Hoescht 33258 dye
(Polysciences, Warrington PA), and neutral-
ized with an equimolar amount of hydrochlo-
ric acid. Fluorescence was measured in a
Hoefer TKO 100 DNA Fluorometer (Hoefer
Scientific Instruments, San Francisco, CA)
against a salmon sperm DNA standard
(Invitrogen, Carlsbad, CA).
Animal treatments. All procedures per-
formed on animals were approved by the
Institutional Animal Care and Use Committee
of the Indiana University School of Medicine.
Animals were treated humanely and with
regard for the alleviation of suffering. Adult
BALB/c and wild-type (WT) C57BL/6 mice
were purchased from Harlan (Indianapolis);
ER-αKO mice (in C57BL/6 background for
> 10 generations) were derived from an in-
house colony. Animals were ovariectomized at
6–8 weeks of age, and 3 weeks later, they were
treated for either 3 or 34 days with vehicle or
test compound. In brief, groups of ﬁve or six
animals were treated daily by either subcuta-
neous injection (sc) or oral gavage (po) with
either vehicle control, EB (10 µg/kg), or
DE-71 (50 mg/kg for 34 days or with 75, 150,
or 300 mg/kg for 3 days). Some groups were
cotreated with EB plus DE-71. Chemicals
were ﬁrst dissolved in DMSO and then diluted
in corn oil and administered at 0.1 mL for po
or at 10–20 µL for sc. Doses were prepared
based on the average body weight measured for
each group on the ﬁrst day of treatment. On
the day after the last treatment, animals were
sacriﬁced by decapitation, and blood was col-
lected by exsanguination. Serum was collected
and stored at –20°C until analysis for individ-
ual BDE congeners and their hydroxylated
metabolites [reported by Qiu et al. (2007)].
The liver was perfused in place with phos-
phate-buffered saline through the hepatic por-
tal vein. The uterus and liver were weighed and
expressed on a per gram of body weight basis.
One uterine horn and the vagina were ﬁxed in
Bouin’s solution overnight. The liver was ﬂash-
frozen in liquid nitrogen and then stored at
–70°C. The fixed uterus and vagina were
embedded in parafﬁn, and 5-µm cross-sections
were stained with hematoxylin and eosin for
analysis by light microscopy. Using an image
analysis program (IPLab, version 3.5 imaging
software; Scanalytics Inc., Fairfax, VA), UEH
and VET were measured as estrogen-sensitive
end points.
Cytochrome P450 (CYP) activity assays.
For each animal, about 0.2 g of frozen liver
was homogenized in 1 mL high-sucrose buffer
[0.15 M potassium chloride, 0.5 M Tris,
1 mM EDTA, 0.25 M sucrose, 0.2 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 20 µM
butylated hydroxytoluene (BHT), pH 7.4] and
centrifuged at 9,000 × g for 20 min at 4°C. To
obtain the microsomal fraction, we centrifuged
the resulting supernatant at 105,000 × g and
4°C for 60 min; the pellet was washed in
potassium pyrophosphate buffer (0.1 M potas-
sium pyrophosphate, 1 mM EDTA, 0.2 mM
PMSF, 20 µM BHT, pH 7.4) by resuspending
it using disposable homogenizing microtubes
and pestles (Kontes Glass Company, Vineland,
NJ). The protein content of the microsomal
preparation was determined using the Pierce
BCA Protein Assay Kit (Pierce, Rockford, IL)
against a bovine serum albumin standard.
The liver samples from each animal were
assayed in duplicate.
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Figure 1. DE-71 induced proliferation of MCF-7 cells treated for 10 days with DE-71 and/or E2 at the indi-
cated concentrations. Proliferation was measured using the MTT assay (A, C, D) or a DNA assay (B). The
antiestrogen fulvestrant (ICI, 10 nm) blocked the effect of DE-71 (C). DE-71 blocked the effect of E2 in a
dose-dependent manner (D). Values shown are mean ± SE of three to seven independent assays. 
*p < 0.05, **p < 0.01,and #p < 0.001 vs. vehicle; ##p < 0.01, and †p < 0.001 vs. treatment without ICI. 
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#We measured 7-ethoxyresoruﬁn O-dealkyla-
tion (EROD; CYP1A) activity and 7-pentoxy-
resorufin O-dealkylation (PROD; CYP2B)
activity by mixing 5 µL of sample with 5 µL
250 µM NADPH and 3.4 µL 0.6 mM
7-ethoxyresorufin or 7-pentoxyresorufin in
1.2 mL 0.1 Tris buffer at 37°C. After allowing
the mixture to equilibrate for 1 min, ﬂuores-
cence was measured at 530 nm excitation and
585 nm emission in a fluorometer at 1-sec
intervals over the course of 1 min. Similar
measurements were made with six different
resoruﬁn concentrations to determine a stan-
dard curve. The slope of the linear range for
each activity assay (Δfluorescence/sec) was
converted to moles of resoruﬁn per gram per
second (mol/g*sec) using the standard curve
and the protein content of each sample.
Statistics. All statistics were performed
using GraphPad Prism, version 3.0a, for
Macintosh (GraphPad Software, San Diego,
CA). For each statistical analysis, we used
Bartlett’s test to determine if groups had
unequal variances. Group averages with equal
variances were compared to each other by
either one-way analysis of variance (ANOVA)
with Tukey post-test or unpaired t-test as
appropriate. Group averages with unequal vari-
ances were compared to each other by t-test
with Welch’s correction. Groups treated with
DE-71 alone were analyzed against vehicle
controls. Groups cotreated with DE-71 and
EB were analyzed against controls treated with
EB alone. All values are expressed as mean ±
SE. Groups were considered statistically differ-
ent if the result of ANOVA with Tukey post-
test or t-test (two-tailed) had p < 0.05;
however, in some instances, means were con-
sidered of borderline statistical signiﬁcance if
0.05 < p < 0.10. DE-71 dose–response studies
were also subjected to regression analysis using
three curve ﬁtting models: a) linear: response =
(slope × dose) + intercept; b) sigmoidal:
response = minimum + (maximum – mini-
mum) ÷ { 1+1 0 [Log(EC50) – Log(dose)] × Hillslope};
c) modiﬁed Gaussian distribution: response =
minimum + ({maximum – minimum}
× exp{–[log(dose) – A] ÷ slope}2, where A =
Log(EC50) + 0.833 × slope, and the EC50 is
the median effective concentration. The best
ﬁtting curve appears in graphs if R2 > 0.8. 
Results
Cell proliferation assays. We compared the
capacity of DE-71 to increase breast cancer cell
(MCF-7) proliferation with that of E2. Both E2
and DE-71 were able to signiﬁcantly increase
cell number, as determined by the MTT assay
(Figure 1A). DNA assays conﬁrmed this ﬁnd-
ing, indicating that the increase in reduced
MTT was caused by an increase in cell number
and was not merely an effect on the cell redox
systems (Figure 1B). The effects of both E2
and DE-71 were negated by cotreatment with
the estrogen antagonist ICI (Figure 1C).
DE-71 produced a biphasic dose–response
curve, suggesting that it may have been toxic to
MCF-7 cells at concentrations > 2.5 × 10–5 M
(Figure 1A). At those same concentrations, we
observed an accumulation of a white precipi-
tate, suggesting a solubility problem.
Cotreatment of cells with both E2 and DE-71
resulted in a lesser increase in cell proliferation
compared with E2 alone, suggesting an antag-
onistic effect of DE-71 on E2-induced cell
proliferation (Figure 1D). Antagonism was
dose dependent; the highest dose tested corre-
sponds to that which produced maximal pro-
liferative effect when cells were treated with
DE-71 alone.
Three-day mouse estrogenic end points. We
used a 3-day treatment regimen in OVX
BALB/c mice to assess DE-71 effects at three
doses (75, 150, and 300 mg/kg); groups of ani-
mals were also treated with 10 µg/kg EB plus
DE-71 at each of these doses. Uterine wet
weight, UEH, and VET were used as estro-
genic end points. DE-71 administration by sc
alone had no statistically significant effect
(Figure 2). However, the increase in uterine
wet weight induced by 10 µg/kg EB was
enhanced by DE-71 in a dose-dependent man-
ner; this enhanced response was equivalent to
the maximal estrogen effect produced by
10 mg/kg EB (Figure 2B). Oral DE-71 admin-
istration had no effect on any of the estrogenic
parameters measured (data not shown).
Subcutaneous DE-71 treatment alone had
no effect on UEH or VET (Figure 2C, 2E).
When mice were cotreated with DE-71 and
EB, there was an increasing dose–response
trend for UEH and VET (Figure 2D, 2F).
However, only borderline statistical signifi-
cance was achieved for UEH in the highest
dose group, and neither trend yielded a good
ﬁt by regression analysis.
Thirty-four-day mouse estrogenic end
points. We determined estrogenic effects in
ovariectomized BALB/c and C57BL/6 WT
and ER-αKO mice treated long-term
(34 days). We examined uterine and vaginal
parameters as in the 3-day assay. As with the
3-day assay, oral DE-71 administration had
no effect on any of the estrogenic parameters
DE-71 estrogenicity 
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Figure 2. Dose effects of DE-71 on uterus and vagina in ovariectomized BALB/c mice treated sc for 3 days
with DE-71 alone at the indicated doses (A,C,E) or with 10 µg/kg EB plus DE-71 (B,D,F). Abbreviations: bw,
body weight; UW, uterine weight. (A,B) UW. (C,D) UEH. (E,F) VET. For (A–F), control means are shown as a
dashed line; blue shaded areas indicate SE. Effects after 3 days of treatment with 10 mg/kg of EB are shown
as a reference for maximal estrogen effect on uterine weight (B), UEH (D), and VET (F); dashed lines indi-
cate the mean; gray shaded areas indicate SE. Values represent means ± SE of 8–10 mice per group. 
*p < 0.05, and **p < 0.01 indicate that individual UWs were signiﬁcantly different from EB controls. 
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C57Bl/6 mice were not treated orally.
Treatment for 34 days with sc DE-71
alone produced no signiﬁcant change in uter-
ine weight (Figure 3A). There was a large
increase (8- to 12-fold; p < 0.001) in uterine
weight of WT mice after E2 treatment. The
uterine weight response to 10 µg/kg EB at
34 days was similar to the increase produced
by 10 mg/kg EB for 3 days; that is, the
34-day EB treatment produced the maximal
uterotrophic effect. EB-induced uterine
weight was unaffected by cotreatment with
DE-71 (Figure 3A).
In BALB/c mice, DE-71 administered sc
for 34 days caused a 23% increase in UEH
(Figure 3C) and a 33% increase in VET
(Figure 3E). When administered alone,
DE-71 had no effect on these parameters in
C57BL/6 mice. In contrast, we observed a
small but statistically significant decrease in
the estrogen-induced UEH increase in
BALB/c mice cotreated with sc DE-71
(Figure 3D). The similar decrease in UEH in
cotreated C57BL/6 mice was not statistically
signiﬁcant. Cotreatment did not alter the EB-
induced increase in VET (Figure 3F).
As expected, EB treatment had no effect
on ER-αKO uterine weights, UEH, or VET,
nor did DE-71 have an effect on any of the
uterine or vaginal parameters in either WT
C56BL/6 mice (Figure 3) or ER-αKO ani-
mals (data not shown).
Liver end points. We determined liver
weights and activities of CYP1A and CYP2B
enzymes. We found a 20–51% increase in
liver weight in BALB/c mice treated with
DE-71 for 34 days compared with vehicle
control, whereas livers of 3-day treated mice
increased in weight up to 39% in a dose-
dependent manner (Figure 4).
EB treatment did not increase liver weight
in BALB/c mice. However, EB potentiated
the effect of po DE-71 but had no effect on sc
DE-71 treatments (Figure 4B). As with
BALB/c mice, the livers of DE-71 treated
C57BL/6 WT mice were 27–29% larger than
vehicle-treated controls. E2 administered
alone or in combination with DE-71 had no
effect on liver weights of C57BL/6 WT mice.
The size of ER-αKO mouse livers increased
30% after DE-71 treatment (Figure 4C).
We found a large increase in PROD activ-
ity in DE-71–treated BALB/c mice compared
with controls, about 7-fold in the po-treated
group and 5-fold in the sc-treated group
(Figure 5A). Still, PROD activity in the
DE-71–induced animals was much lower than
EROD activity in vehicle-treated animals (i.e.,
the maximal PROD was about one-third the
minimal EROD activity). Liver microsomal
EROD activity also increased (2.5-fold), but
only for po-treated mice (Figure 5B). EB
treatment had no effect on either EROD or
PROD activity (data not shown).
Discussion
DE-71 exhibited both estrogenic and anti-
estrogenic effects in the MCF-7 cell prolifera-
tion assay and in the adult ovariectomized
mouse model, a behavior expected from a
weak ER agonist (reviewed by Lerner and
Jordan 1990). The observation that ICI pre-
vented DE-71 from increasing cell number in
the MCF-7 bioassay suggests the involvement
of an ER.
To date, this is the ﬁrst report of a study in
which the estrogenic action of a PBDE mix-
ture has been examined using standard rodent
bioassay end points. The magnitude of the
effects seen in our in vivo studies was similar to
those produced by treatment of ovariectomized
rats with 200 mg/kg BDE-47, a major compo-
nent of DE-71 (Dang et al. 2007). The type of
response observed (agonist or antagonist) was
dependent upon the duration of exposure to
DE-71. In the 3-day assay DE-71 administered
alone produced no estrogenic effects; however,
when it was administered for 34 days, it pro-
duced hypertrophy of the uterine epithelium
and hyperplasia of the vaginal epithelium.
When administered with EB in the 3-day
treatment schedule, DE-71 enhanced the
estrogen effect, whereas in the 34-day treat-
ment schedule DE-71 produced small anti-
estrogenic effects. Thus, pharmacokinetic
considerations are paramount when designing
further studies of PBDE action in vivo.
We used the ER-αKO mouse to deter-
mine if in vivo effects of DE-71 were medi-
ated by ER-α; however, because there was a
lack of any estrogenic effects of DE-71 in
C57BL/6 WT mice, this experiment was not
informative. The observation that DE-71
could enhance estrogenic effects beyond those
produced by a saturating dose of EB suggests
that PBDEs modify estrogen action through
nonclassical pathways, as has been proposed for
other xenobiotics such as β-hexachlorocyclo-
hexane (Hatakeyama et al. 2002; Steinmetz
et al. 1996).
PBDEs are suspected to behave as estro-
gens because of the similarity of their chemical
structure and properties to other xenobiotics,
mainly the polychlorinated biphenyls
[reviewed by Hooper and McDonald (2000),
Meerts et al. (2001), and Pijnenburg et al.
(1995)]. Furthermore, hydroxylated metabo-
lites of PCBs have been shown to exert estro-
genic effects [reviewed by Bigsby et al. (2005)
and Blair et al. (2000)]; therefore, it may be
reasonable to expect that hydroxylated forms of
Mercado-Feliciano and Bigsby
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Figure 3. Effects of DE-71 in uterus and vagina of ovariectomized BALB/c and C57BL/6 WT mice treated for
34 days with DE-71 alone (A,C,E) or E2 plus DE-71 (B,D,E). Abbreviations: bw, body weight; UW, uterine
weight. (A,B) Relative UW. (C, D) UEH. (E,F) VET. Values shown are mean ± SE of 5–10 mice per group. 
*p < 0.05, **p < 0.01, and #p < 0.001 vs. corresponding control. 
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)PBDEs would also be estrogenic. Several
researchers have shown that individual BDE
congeners or certain synthetic hydroxylated
congeners could exert estrogenic effects in cul-
tured cells. In estrogen-responsive transcription
reporter assays, BDE-28 and BDE-100, as well
as the 4´-hydroxy forms of BDE-30 and
BDE-119, proved to be estrogenic (Meerts
et al. 2001). In addition, several BDE con-
geners found in DE-71 were mildly anti-
estrogenic in the same assay. Likewise, Hamers
et. al. (2006) observed weak estrogenic activity
by several low-brominated BDEs, weak anti-
estrogenic activity for tetra- and hepta-bromi-
nated BDEs and 6OH-BDE-47, and neither
activity for the DE-71 mixture.
Our results show that in the OVX mouse
sc DE-71 produced very small estrogenic
effects, whereas po DE-71 had no effect.
Because DE-71 had estrogenic effects in cell
culture, the lack of effect in po-treated mice
suggests rapid clearance via liver metabolism.
However, when we analyzed plasma of mice
that had been treated with DE-71 for 34 days,
we found similar amounts of parent com-
pounds and metabolites in the blood of either
sc- or po-treated animals, with the exception of
BDE-153, which was 5 times higher in the po
group (Qiu et al. 2007). Furthermore, the con-
centration of total DE-71 congeners was
approximately 1,000–2,000 ng/mL, similar to
what would be achieved with 2–4 µM treat-
ment in culture, where 1 µM was minimally
effective and 5 µM showed an effect that was
approximately 50% of the maximal E2-induced
effect. Staskal et al. (2005) found that non-
metabolized BDE-47 is rapidly cleared in the
mouse. This process is mediated by urinary
proteins and may be saturated after repeated
exposure (Diliberto et al. 2007; Staskal et al.
2006). Because the animals were treated long-
term with a high dose of DE-71, it is possible
that the concentrations we found in blood rep-
resent a steady-state level reached when urinary
clearance is at its maximum capacity. Although
this may explain why the po- and sc-treated
animals had similar blood concentrations of
most PBDEs, it does not explain why the sc
route produced estrogenic effects while the
po route did not. Another explanation is that
more PBDE congeners may reach estrogen
targets when administered sc rather than po. It
is possible that sc-administered PBDEs reached
higher levels in peripheral tissue than liver
compared with po-administered PBDEs by
avoiding the high activity of conjugating
(phase II) enzymes in the liver and gut
(Cassidy and Houston 1984; Li et al. 2004). It
is also possible that PBDEs are activated by
CYP in peripheral tissues such as adipose or at
the estrogen-target tissues (Shimada et al.
2003, Yoshinari et al. 2006). Others have also
seen higher efﬁcacy of sc dosing over po dosing
of estrogens, as is the case of the xenoestrogen
bisphenol A (Berger et al. 2007) and steroidal
estrogen (Savvas et al. 1992).
The MCF-7 cell proliferation assay used
here to test DE-71 is probably more sensitive
than the reporter gene expression system used
by others (Hamers et al. 2006; Legler et al.
1999) due to the longer time of incubation
with the chemical (10 days vs. 24 hr), thereby
allowing accumulation of both the PBDE con-
geners inside the cell [increased intracellular
concentration (Mundy et al. 2004)] and the
estrogenic effect (cell growth). Alternatively,
MCF-7 cells are known to express CYP
enzymes (Barber et al. 2006; Peters et al.
2004), and it may be that during the 10-day
incubation they metabolically convert BDE
congeners to more active hydroxylated forms.
Other researchers have shown that both
BDE-99 and DE-71 interfere with rodent
sexual development after prenatal exposure
(Ceccatelli et al. 2006; Kuriyama et al. 2005;
Lilienthal et al. 2006), but speciﬁc hormonal
activity involved was not demonstrated. As
noted by Ceccatelli et al. (2006), PBDE
remains in the offspring for months after
birth, making it impossible to determine if the
observed increase in expression of estrogen tar-
get genes during adulthood was due to devel-
opmental defects or adult hormone-like effects
(or a combination of both). Although such
research is suitable to assess the sensitivity to
developmental effects, it does not deﬁne these
effects as estrogenic. The pubertal develop-
ment protocol used by Stoker et al. (2004)
and the adult gonadectomized rodent model
used here are more suitable to assess estrogenic
activity by looking at well-known responses to
estrogen after chemical challenge. Classic
estrogenic responses such as increased uterine
weight, UEH, and VET in the adult OVX
mouse are a strong indication of the involve-
ment of estrogen-signaling pathways and are
standard methods to assess estrogenicity of a
chemical (Clode et al. 2006).
We found differences in responses between
mouse strains: The uterine and vaginal epithe-
lium seems to be more sensitive to the effects
of DE-71 in BALB/c mice than in C57BL/6
mice. Others have shown that C57BL/6 mice
exhibit higher sensitivity to estrogen compared
with other strains (Silberberg and Silberberg
1951; Spearow et al. 1999, 2001), but BALB/c
mice were not included in those comparisons.
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Figure 5. Effects of DE-71 on liver microsomal CYP activity in BALB/c mice treated for 34 days with DE-71
alone or with EB plus DE-71. (A) PROD (CYP2B) activity. (B) EROD (CYP1A) activity. Values shown are mean
± SE. n = 8 mice per group. 
*p < 0.05, and **p < 0.01 vs. vehicle. 
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Figure 4. Effects of DE-71 on liver weight of mice were treated for either 3 (A) or 34 (B,C) days with DE-71 alone or with E2 and DE-71. Controls for the 34-day time
point were treated po with vehicle. Values shown are mean ± SE (n = 5–10 mice per sc group; n = 4–5 mice per po group). 
*p < 0.05, **p < 0.01, and #p < 0.001 vs. vehicle. ##p < 0.05 vs. DE-71 at the same dose without EB. 
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#Although our ﬁndings may illustrate a real dif-
ference in estrogen sensitivity between the
BALB/c and C57BL/6 strains, an alternative
explanation is that between-assay variability
makes it difﬁcult to measure small estrogenic
effects (Ashby et al. 2004; Thigpen et al. 2002;
Tinwell et al. 2000).
DE-71 increased liver weight in both
BALB/c and C57BL/6 mice treated for
34 days, an effect shown previously in rats
(Stoker et al. 2004; Zhou et al. 2001, 2002)
and mink (Martin et al. 2007). The fact that a
similar increase in liver weight occurred in
ER-αKO mice indicates that this is not
dependent on ER-α signaling. An increase in
liver weight may occur in parallel with histo-
logic changes such as hepatocytomegaly, aci-
dophilic cytoplasm, binucleated hepatocytes,
and eosinophilic bodies (Hardy et al. 2002;
Son et al. 2007). Although we did not analyze
the tissue histologically, others have shown
that oral administration of DE-71 to rats for
up to 90 days resulted in increased liver
weights, with concomitant histologic changes
(International Programme on Chemical Safety
1994). In BALB/c mice treated for 3 days,
DE-71 increased liver weight in a dose-depen-
dent manner only when administered po.
Interestingly, EB potentiated the DE-71–
induced increase in liver weight in BALB/c
but not in C57BL/6 mice. Previous studies
have shown that an estrogen-induced increase
in liver weight in mice is strain dependent
(Buchanan et al. 2002; Duffel et al. 1981;
Goodin et al. 2002; Wang et al. 2004).
Because DE-71 treatment increased liver
weight while at the same time diminishing the
action of administered EB on the uterine
epithelium (34-day treated mice only), it is
possible that DE-71 can alter liver metabolic
pathways that regulate systemic estrogen activ-
ity. A major pathway responsible for E2 deacti-
vation is catalyzed by CYP enzymes, and of
those CYP1A have the highest activity for E2
hydroxylation (Lee et al. 2003). A less active
enzyme, CYP2B, also may be involved in E2
hydroxylation (Acevedo et al. 2005).
Induction of hepatic EROD (CYP1A activity)
and PROD (CYP2B activity) has been shown
in rats (Stoker et al. 2004; Zhou et al. 2001,
2002) and mink (Martin et al. 2007) treated
with DE-71 and mice treated with Bromkal
70-5 DE, a PBDE mixture with congener
composition similar to DE-71 (Lundgren
et al. 2007). In the present study, EROD
(CYP1A) was increased by DE-71 but only
when administered orally. PROD (CYP2B)
was increased by DE-71 regardless of the route
of administration, but the increase occurred to
a much greater extent when the po route was
used. Because the small antiestrogenic effect
observed in the uterine epithelium occurred
only when DE-71 was administered sc, it does
not appear that this effect can be attributed to
altered estrogen metabolism through increased
CYP1A or CYP2B.
Individual PBDE congeners are known to
induce expression of CYP2B, but the induc-
tion of CYP1A activity by PBDEs is most
likely due to contamination with polybromi-
nated dibenzo-p-furans (Hanari et al. 2006;
Kuiper et al. 2006), which are known to
induce aryl hydrocarbon receptor signaling in
mammals (Olsman et al. 2007). Sanders et al.
(2005) found that both DE-71 and its three
main component congeners (BDEs 47, 99,
and 153) increased CYP2B gene expression in
rats, but that only DE-71 and not the indi-
vidual congeners strongly up-regulated
CYP1A, thus suggesting that the CYP1A
increase was due to furan contamination of
the DE-71 mixture. Because furans do not
induce CYP2B, PROD induction is most
likely mediated by PBDE activation of the
constitutive androstane receptor, CAR
(reviewed by Yamada et al. 2006).
In summary, the PBDE mixture DE-71
behaves as a weak estrogen in both MCF-7
breast cancer cell proliferation and the ovariec-
tomized adult mouse models. The anti-
estrogenic activity may be due to an interaction
with ERs, not to a metabolic depletion of
coadministered estrogens. In animal studies,
treatment route and duration determined
whether DE-71 was estrogenic or not. BALB/c
mice are more susceptible to DE-71 effects in
estrogen target tissues and in liver than
C57BL/6 mice. DE-71 also increased liver
weight in both mouse strains tested, and this
effect was not dependent on ER-α. It still
remains to be seen if the above listed effects of
DE-71 are due to the original BDE congeners
or to their hydroxylated metabolites.
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